2alv: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2alv.png|left|200px]] | [[Image:2alv.png|left|200px]] | ||
{{STRUCTURE_2alv| PDB=2alv | SCENE= }} | {{STRUCTURE_2alv| PDB=2alv | SCENE= }} | ||
===X-ray structural analysis of SARS coronavirus 3CL proteinase in complex with designed anti-viral inhibitors=== | ===X-ray structural analysis of SARS coronavirus 3CL proteinase in complex with designed anti-viral inhibitors=== | ||
{{ABSTRACT_PUBMED_16250632}} | {{ABSTRACT_PUBMED_16250632}} | ||
==About this Structure== | ==About this Structure== | ||
[[2alv]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Sars_coronavirus Sars coronavirus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2ALV OCA]. | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:016250632</ref><references group="xtra"/> | ||
[[Category: | [[Category: Sars coronavirus]] | ||
[[Category: Baker, S C.]] | [[Category: Baker, S C.]] | ||
[[Category: Fu, W.]] | [[Category: Fu, W.]] | ||
| Line 40: | Line 28: | ||
[[Category: Anti-viral]] | [[Category: Anti-viral]] | ||
[[Category: Coronavirus]] | [[Category: Coronavirus]] | ||
[[Category: Hydrolase]] | |||
[[Category: Inhibitor]] | [[Category: Inhibitor]] | ||
[[Category: Protease]] | [[Category: Protease]] | ||
[[Category: Proteinase]] | [[Category: Proteinase]] | ||
[[Category: Sar]] | [[Category: Sar]] | ||
Revision as of 13:49, 6 January 2013
Template:ABSTRACT PUBMED 16250632
About this StructureAbout this Structure
2alv is a 1 chain structure with sequence from Sars coronavirus. Full crystallographic information is available from OCA.
ReferenceReference
- ↑ Ghosh AK, Xi K, Ratia K, Santarsiero BD, Fu W, Harcourt BH, Rota PA, Baker SC, Johnson ME, Mesecar AD. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem. 2005 Nov 3;48(22):6767-71. PMID:16250632 doi:10.1021/jm050548m